Early HCC: Diagnosis and molecular markers

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. HCC occurs mainly in patients with chronic liver disease such as in hepatitis B and C infection. These high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by imaging diagnosis. They are now widely recognized as a precursor or early stage of HCC and are classified as dysplastic nodules or early HCC. It is considered that early HCC is a key step in the process of HCC development and progression. However, the molecular mechanisms of early hepatocarcinogenesis are far from clear. Specific mutations of classical oncogenes or tumor suppressor genes have not been identified in early HCC so far. Recent progress in comprehensive analysis of gene expression is shedding some light on this issue. It has been reported that HSP70, CAP2, glypican 3, and glutamine synthetase could serve as molecular markers for early HCC. Further analysis is expected to evaluate their usefulness in routine pathological diagnosis including biopsy diagnosis and also as serum markers for early detection of HCC.

Original languageEnglish
Pages (from-to)108-111
Number of pages4
JournalJournal of Gastroenterology
Volume44
Issue numberSUPPL. 19
DOIs
Publication statusPublished - 2009

Fingerprint

Hepatocellular Carcinoma
Glypicans
Glutamate-Ammonia Ligase
Hepatitis C
Tumor Suppressor Genes
Hepatitis B
Oncogenes
Liver Diseases
Chronic Disease
Biomarkers
Biopsy
Gene Expression
Mutation
Infection
Neoplasms

Keywords

  • CAP2
  • GPC3
  • Hepatocellular carcinoma
  • HSP70

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Early HCC : Diagnosis and molecular markers. / Sakamoto, Michiie.

In: Journal of Gastroenterology, Vol. 44, No. SUPPL. 19, 2009, p. 108-111.

Research output: Contribution to journalArticle

@article{38e7f403ae7942368ef5fcf1b2afc76b,
title = "Early HCC: Diagnosis and molecular markers",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. HCC occurs mainly in patients with chronic liver disease such as in hepatitis B and C infection. These high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by imaging diagnosis. They are now widely recognized as a precursor or early stage of HCC and are classified as dysplastic nodules or early HCC. It is considered that early HCC is a key step in the process of HCC development and progression. However, the molecular mechanisms of early hepatocarcinogenesis are far from clear. Specific mutations of classical oncogenes or tumor suppressor genes have not been identified in early HCC so far. Recent progress in comprehensive analysis of gene expression is shedding some light on this issue. It has been reported that HSP70, CAP2, glypican 3, and glutamine synthetase could serve as molecular markers for early HCC. Further analysis is expected to evaluate their usefulness in routine pathological diagnosis including biopsy diagnosis and also as serum markers for early detection of HCC.",
keywords = "CAP2, GPC3, Hepatocellular carcinoma, HSP70",
author = "Michiie Sakamoto",
year = "2009",
doi = "10.1007/s00535-008-2245-y",
language = "English",
volume = "44",
pages = "108--111",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "SUPPL. 19",

}

TY - JOUR

T1 - Early HCC

T2 - Diagnosis and molecular markers

AU - Sakamoto, Michiie

PY - 2009

Y1 - 2009

N2 - Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. HCC occurs mainly in patients with chronic liver disease such as in hepatitis B and C infection. These high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by imaging diagnosis. They are now widely recognized as a precursor or early stage of HCC and are classified as dysplastic nodules or early HCC. It is considered that early HCC is a key step in the process of HCC development and progression. However, the molecular mechanisms of early hepatocarcinogenesis are far from clear. Specific mutations of classical oncogenes or tumor suppressor genes have not been identified in early HCC so far. Recent progress in comprehensive analysis of gene expression is shedding some light on this issue. It has been reported that HSP70, CAP2, glypican 3, and glutamine synthetase could serve as molecular markers for early HCC. Further analysis is expected to evaluate their usefulness in routine pathological diagnosis including biopsy diagnosis and also as serum markers for early detection of HCC.

AB - Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. HCC occurs mainly in patients with chronic liver disease such as in hepatitis B and C infection. These high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by imaging diagnosis. They are now widely recognized as a precursor or early stage of HCC and are classified as dysplastic nodules or early HCC. It is considered that early HCC is a key step in the process of HCC development and progression. However, the molecular mechanisms of early hepatocarcinogenesis are far from clear. Specific mutations of classical oncogenes or tumor suppressor genes have not been identified in early HCC so far. Recent progress in comprehensive analysis of gene expression is shedding some light on this issue. It has been reported that HSP70, CAP2, glypican 3, and glutamine synthetase could serve as molecular markers for early HCC. Further analysis is expected to evaluate their usefulness in routine pathological diagnosis including biopsy diagnosis and also as serum markers for early detection of HCC.

KW - CAP2

KW - GPC3

KW - Hepatocellular carcinoma

KW - HSP70

UR - http://www.scopus.com/inward/record.url?scp=58849087179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849087179&partnerID=8YFLogxK

U2 - 10.1007/s00535-008-2245-y

DO - 10.1007/s00535-008-2245-y

M3 - Article

C2 - 19148803

AN - SCOPUS:58849087179

VL - 44

SP - 108

EP - 111

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - SUPPL. 19

ER -